Transplantation of the heart: An overview of 40 years' clinical and research experience at Groote Schuur Hospital and the University of Cape Town: Part I. Surgical experience and clinical studies by Hassoulas, J
Forum
347  June 2012, Vol. 102, No. 6  SAMJ
Orthotopic heart transplantation
Christiaan Barnard and his team performed the world’s first human-to-
human heart transplant operation on 3 December 1967. It was a major 
historical event and a significant breakthrough for medical science. This and 
subsequent events received front-page media coverage around the world for 
months on end, describing all aspects in detail and giving progress reports 
on the postoperative course of the patients.
Between December 1967 and November 1974, exclusively orthotopic 
heart transplantation was performed. Ten such heart transplants were 
done, and a heart and lung transplant was also performed in 1971.1-6 
Of the 10 patients who received orthotopic heart transplants, 4 lived 
for more than 18 months; 2 of them became long-term survivors, one 
living for over 13 years and the other for over 24 years. This last patient 
is remarkable not only for the length of his survival but for excellent 
recovery from the operation in spite of severe cardiac atherosclerosis at 
the time of the surgery. Within 3 months he had returned to work and did 
not miss a single day’s work until he retired 15 years later. He died from 
a cerebrovascular accident after unsuccessful peripheral vascular surgery 
and lower limb amputations.
In the 1971 transplantation of a heart and both lungs, the heart was 
placed in the orthotopic position and the lungs were transplanted separately 
at the left and right main bronchi. The patient died 23 days later from 
pneumonia and bronchopleural fistula complications. This operation was 
considered quite an achievement, as two such operations were performed 
in the USA at about the same time, but the patients did not survive longer 
than a day or two. This early experience established sound criteria for the 
selection of recipients who would derive maximum benefit from heart 
transplantation. Experience was also obtained in methods of diagnosis and 
treatment of acute rejection.7,8
Heterotopic heart transplantation
Clinical experience with orthotopic heart transplantation showed that 
complex and difficult-to-manage situations often emerge. It has been 
established that full recovery of donor heart function takes place over hours 
to days after transplantation. Anoxic damage and myocardial cell necrosis 
of the graft can occur during harvesting or at implantation, especially if 
myocardial protection has been inadequate or prolonged. Air embolisation 
to the coronary arteries often contributes to this situation. However, such 
damage is mostly caused by the excessive catecholamine secretion that 
results from brain death of the donor. Poor function of the donor heart has 
resulted in many recipient deaths. Similarly, many recipient deaths occurred 
as a result of pulmonary hypertension, as the donor right ventricle is 
unaccustomed to pumping against elevated pulmonary pressures, resulting 
in acute irreversible right heart failure. The recipient’s right ventricle, 
although diseased, has adapted with time and has hypertrophied, making 
it capable of maintaining the pulmonary circulation.
These observations were cause for serious concern and led Christiaan 
Barnard to the conception of a completely original method of heterotopic 
heart transplantation, the surgical technique of which has been described 
in detail.9 Additional advantages in the application of this technique were 
anticipated at the time. We consider that the ensuing 9-year period of 
experience (November 1974 - December 1983) with clinical heterotopic 
heart transplantation has confirmed that our earlier observations and 
anticipations were correct.10,11 
Survival rates for patients at 1 and 5 years increased from less than 
40% and 20%, respectively, with orthotopic transplantation to over 60% 
and 36%, respectively, when the heterotopic method was used. Forty-nine 
consecutive heterotopic heart transplants were performed on 43 patients 
during this 9-year period. We believe that the heterotopic method of heart 
transplantation has proven advantageous and that its wider application is 
therefore justified. 
The cyclosporin A era
From 1983 onwards the use of cyclosporin A together with much-reduced 
amounts of corticosteroids was started. The ‘corticosteroid-sparing’ effect 
of cyclosporin A looked promising at the time. When using cyclosporin A 
for immunosuppression, the only reliable means available to diagnose graft 
rejection remains endomyocardial biopsy of the donor heart.
The cyclosporin A era resulted in the recommencement of orthotopic 
heart transplantation and the gradual decrease of heterotopic heart 
transplantation at Groote Schuur Hospital over the next few years. The 
vast majority of heart transplants performed during the next 20 years were 
orthotopic, and the total number of transplants performed until 2003 was 
489 (Fig. 1).
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The heart transplant programme at Groote Schuur Hospital and the 
University of Cape Town has continued uninterruptedly since the first 
human transplant in 1967. Orthotopic heart transplantation was followed 
by the heterotopic method in 1974, considerably improving the clinical 
results. In 1983, owing to the advent of cyclosporin A, the orthotopic 
method was once again predominantly adopted. Early graft failure for 
various reasons remains a major complication, and heterotopic heart 
transplantation is perhaps the best way to deal with it.
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Although cyclosporin A has to some extent decreased complications 
due to rejection after transplantation, many other causes of possible 
complications in the early postoperative period remain12 and are a major 
cause for concern in heart transplantation units. We think that many of 
them could be circumvented by the use of heterotopic heart transplantation, 
and that its wider use should be seriously reconsidered. 
Clinical studies
Haemodynamic evaluation of the heterotopically 
transplanted heart13-15
Before its clinical application, this method of heart transplantation was 
extensively investigated and validated in the experimental laboratory. The 
technical feasibility, ease and simplicity of the operation were demonstrated. 
It was proven that the space occupied by the transplanted heart in front of 
the right lung hilum does not contribute to mechanical or physiological 
ventilatory complications. Bronchograms performed about 2 years later on 
the second heterotopic heart transplant recipient demonstrated minimal 
compression of the right lung.
In several experiments involving biventricular bypass it was found that 
by selectively fibrillating the recipient heart, the donor heart was capable 
of effectively supporting the total circulation. Intracardiac pressures and 
cardiac output measurements detected minor and statistically insignificant 
changes from the normal range.
Full cardiac catheterisation studies of long-term surviving patients 
are performed annually, primarily to detect coronary atherosclerosis 
of the donor heart coronary arteries. These studies, often repeated in 
particular patients over years, have documented normal or near-normal 
haemodynamics at rest. This confirms that, once the hazards of acute 
rejection are overcome, the heterotopically transplanted heart can function 
physiologically and afford the recipient full rehabilitation.
Under conditions of exercise or stress, the heterotopically transplanted 
heart will, like the orthotopic graft, respond in an atypical gradual fashion 
to increase its intrinsic cardiac rate, thereby increasing cardiac output and 
compensating for the increased demand.
The use of pacemaker systems in heterotopic heart 
transplantation16,17
Experimental studies showed that with synchronous pacing of both hearts 
the extensively damaged recipient ventricle failed to open the aortic valve. It 
follows, therefore, that some stasis will occur within this dilated left ventricle 
with the subsequent possibility of thrombus formation.
To avoid this situation, and also to derive maximal circulation 
contribution from the recipient heart, it was elected at one stage to implant 
a permanent pacemaker system in patients undergoing heterotopic heart 
transplantation. This pacemaker system consisted of atrial pacing electrodes 
on the right atria of the donor and recipient heart which were connected 
to two pacemakers of a special design, having a combined atrial sensing 
and a ventricular output electrode socket with a sensing discharge delay of 
200 ms. In one patient a satisfactory long-term function of the pacemaker 
system was achieved; in another multiple complications occurred such as 
stimulation of the diaphragm and rectus muscles and sternotomy infection 
that necessitated its removal. Thereafter no more pacemaker systems were 
inserted, as it was decided that the possible complications far outweigh the 
possible benefits of their use.
Clinical heterotopic heart transplantation after 
prolonged preservation of the donor heart9
After extensive laboratory investigation of methods of prolonged myocardial 
preservation and documentation of adequate function after orthotopic 
transplantation of donor hearts preserved in this way, it was considered 
safe to apply these methods clinically. The donor heart in 4 heterotopic 
heart transplants at the time had undergone prolonged preservation of the 
myocardium. Ischaemic times ranged from 7 to 17 hours.
Prolonged preservation of the myocardium of the donor heart was 
accomplished by initial aortic root perfusion with a hypothermic, 
hyperkalaemic solution, followed by continuous aortic root perfusion 
with an oxygenated hypothermic clear perfusate. For continuous aortic 
root perfusion the donor heart was suspended from the aorta in portable 
apparatus designed for this purpose. The fluid is recycled pneumatically 
using a pressurised gas cylinder of 97% O2 and 3% CO2. The design of this 
apparatus is simple and it is easily transported (but not yet by commercial 
aircraft, as it incorporates a pressurised gas cylinder).
In the immediate postoperative period the function of the donor heart 
was adequate and it shared the circulation with the recipient heart. After a 
few hours postoperatively a gradual increase in contribution towards the 
circulation by the donor heart was observed in all 4 cases. However, the 
function of the heart with the 17-hour preservation period deteriorated 
after a few days and it had to be excised 3 weeks postoperatively, the 
patient remaining alive with his own heart. This deterioration was due to 
irreversible acute rejection. The other 3 patients did very well. Full cardiac 
catheterisation was performed in all 3 at 3 months postoperatively. In 2 
patients the donor heart haemodynamics were excellent. In the 3rd patient, 
although haemodynamics were documented to be good, there was some 
concern since on angiography the donor left ventricular contraction was 
somewhat restricted. This may be related to bouts of acute rejection that 
this patient was experiencing at the time. One of these patients went on to 
be a long-term survivor and lived a normal life for over 12 years.
Although this method of prolonged preservation of the human heart for 
transplantation in the heterotopic position has proved successful, there is 
room for improvement. Further modification of the perfusate solution is 
required to avoid the severe oedema formation currently seen. This may 
be achieved, for instance, by the addition of washed red blood cells to the 
solution. It is unsatisfactory that commercial aircraft cannot transport the 
portable apparatus for the donor heart; this factor must be overcome to 
substantially reduce the cost of obtaining a donor heart.
Paediatric heart transplantation11,18,19
We were the first heart transplant team to successfully perform a heterotopic 
heart transplant in 2 children, aged 13 and 14 years, in 1980 and 1981, 
respectively. Because these patients presented with severe biventricular 
cardiac failure and arrhythmias, adult donor hearts were used as there was 
no time to wait for paediatric donor hearts to become available. The adult 
donor hearts fitted well into the chests of the children and there were no 
problems with lung compression. However, the donor hearts had a large 
stroke volume that caused severe blood pressure elevation in the immediate 
postoperative period. A combination of high doses of various drugs 
intravenously was used to control the high blood pressure, as it resulted in 
severe headache in the children once they were awake and extubated. Over 
the next few days, the donor hearts gradually adapted to the new circulation 
Fig. 1. The Groote Schuur Transplant Registry until the year 2003, showing 
trends and changes that occurred over this time period (kindly provided by 
the Department of Cardiac Surgery, University of Cape Town).
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and the intravenous therapy was steadily decreased until discontinued.
The immunosuppression regimen used was the ‘classic’ combination of 
corticosteroids, azathioprine and antithymocyte globulin with the addition 
of cyclophosphamide or actinomycin D when severe acute rejection episodes 
occurred. For the next 4 - 5 years after transplantation both children did 
extremely well, going back to school and living normal lives. However, as a 
result of the corticosteroids they received, they experienced some abnormal 
physical growth. Chronic rejection set in and both had to be re-transplanted. 
In both cases the new transplant was placed in the orthotopic position after 
removal of the patient’s own heart. Although both previously transplanted 
hearts had developed severe coronary artery atherosclerosis and were in 
danger of myocardial infarction, they still had good myocardial contractility. 
It was therefore decided not to remove them, but to ‘hook’ them to the 
new heart in the heterotopic position. Both operations went well and the 
patients recovered completely. This time they were both commenced on 
cyclosporin A for immunosuppression, which proved more advantageous 
than the previous regimen, and both survived beyond 10 years after the first 
heart transplant. In the second patient, the second heart also failed owing to 
chronic rejection and a third heart transplant was performed, so this patient 
had 4 hearts in his lifetime. The first patient went on to become a long-term 
survivor, being alive at the time of writing more than 31 years after the 
initial heterotopic heart transplant. He has lived a fairly normal and active 
life, for example working as a game ranger for a while and being a hunter 
in the northern parts of South Africa. He has developed complications, but 
they have been successfully managed over the years. In 1990 a pacemaker 
was inserted to treat symptomatic sinus bradyarrhythmias of the orthotopic 
heart, and in 2002 open-heart surgery was undertaken for the placement of 
three coronary artery bypass grafts and a tricuspid valve annuloplasty on the 
orthotopic heart. He made an uneventful recovery from this major cardiac 
surgery. The fact that the second (orthotopic) transplanted heart developed 
chronic rejection (arteriosclerosis on the coronary arteries) almost 20 years 
later attests to the better immunosuppression afforded by cyclosporin A 
compared with the first (heterotopic) transplanted heart, which developed 
rejection 4 years after the operation.
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